Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Biosimilars
Biosimilars
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
Read More
Biosimilars
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell NHL
Read More
Biosimilars
Scaled Integration of FDA-Approved Biosimilars
Read More
Biosimilars
Biosimilar Uptake of Filgrastim and Impact on Spending in Medicare Part D from 2015 to 2019
Read More
Biosimilars
Evaluation of Real-World Cost-Savings and Utilization of Biosimilar Drugs in a Community-Based Oncology Practice
Read More
Biosimilars
Utilization and Clinical Characteristics for the Trastuzumab Originator, Biosimilars, and Other HER2 Inhibitors
Read More
Biosimilars
Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Allowed Budget-Neutral Expanded Access to Antineoplastic Therapy
Read More
Biosimilars
2021 in Review
Read More
Biosimilars
Bioequivalence of Bevacizumab Reference and Its Biosimilar BCD-021 in Nonsquamous NSCLC
Read More
Biosimilars
Five-Year Follow-Up of a Comparative Phase 3 Study of SB3 and Trastuzumab Reference in HER2-Positive Early or Locally Advanced Breast Cancer
Read More
1
2
3
4
5
Page 2 of 7
Results 11 - 20 of 65